Compare IROQ & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IROQ | GANX |
|---|---|---|
| Founded | 1883 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.4M | 117.7M |
| IPO Year | 2011 | 2021 |
| Metric | IROQ | GANX |
|---|---|---|
| Price | $26.40 | $3.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 5.2K | ★ 1.4M |
| Earning Date | 10-31-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 157.16 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $27,979,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.45 | ★ N/A |
| Revenue Growth | ★ 24.68 | N/A |
| 52 Week Low | $22.04 | $1.41 |
| 52 Week High | $26.50 | $3.98 |
| Indicator | IROQ | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 65.18 | 73.17 |
| Support Level | $26.05 | $2.92 |
| Resistance Level | $26.14 | $3.65 |
| Average True Range (ATR) | 0.08 | 0.34 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 87.50 | 95.65 |
IF Bancorp Inc is a holding company mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company, in association, takes deposits from the general public and invests those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, etc., and offers a variety of deposit accounts and alternative delivery channels. In addition to the traditional banking products and services, the group also offers a full line of property and casualty insurance products, annuities, mutual funds, individual securities, managed accounts, and other financial services.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.